Abstract
In vitro studies were conducted to identify the cytochromes P450 (P450s) involved in the formation of 2- and 3-hydroxycarbamazepine, metabolites that may serve as precursors in the formation of protein-reactive metabolites. Human liver microsomes (HLMs) converted carbamazepine (30–300 μM) to 3-hydroxycarbamazepine at rates >25 times those of 2-hydroxycarbamazepine. Both the 2- and 3-hydroxylation of carbamazepine appeared to conform to monophasic Michaelis-Menten kinetics in HLMs (apparentKm values, ∼1640 and ∼217 μM; apparentVmax values, ∼5.71 and ∼46.9 pmol/mg of protein/min, respectively). Rates of carbamazepine 2- and 3-hydroxylation correlated strongly with CYP2B6 activity (r ≥ 0.757) in a panel of HLMs (n = 8). Carbamazepine 3-hydroxylation also correlated significantly with CYP2C8 activity at a carbamazepine concentration of 30 μM. Formation of 2- and 3-hydroxycarbamazepine did not correlate significantly with any other P450 activities. The chemical inhibitors ketoconazole (CYP3A) and 7-EFC (CYP2B6) inhibited both 2- and 3-hydroxycarbamazepine formation whereas 4-methylpyrazole (CYP2E1) markedly decreased 2-hydroxycarbamazepine formation. Several recombinant P450s catalyzed carbamazepine 2- and 3-hydroxylation, but after adjustment for relative hepatic abundance, CYP3A4 and CYP2B6 appeared to be the major catalysts of carbamazepine 3-hydroxylase activity, and at least five P450s were significant contributors to 2-hydroxycarbamazepine formation; CYP2E1 made the greatest contribution to the Clint of carbamazepine 2-hydroxylation (∼30%), but P450s CYP1A2, 2A6, 2B6, and 3A4 also made significant contributions (∼13–18%). These results suggest that CYP2B6 and CYP3A4 are largely responsible for the formation of 3-hyrdoxycarbamazepine, whereas multiple P450s (CYP1A2, 2A6, 2B6, 2E1, and 3A4) contributed to 2-hydroxycarbamazepine formation.
Footnotes
-
Supported in part by Grant R01GM58883–02 (J.S.L.), National Institute of General Medical Sciences.
- Abbreviations used are::
- P450
- cytochrome P450
- DMSO
- dimethyl sulfoxide
- HPLC
- high-performance liquid chromatography
- MS
- mass spectometry
- 1
- iminostilbene
- 2
- dibenzo[b,f]azepin-2-one
- 3
- 5H-dibenzo[b,f]azepin-2-ol
- 4
- 2-(tert-butyl-dimethyl-silanyloxy)-5H-dibenzo[b,f]azepin-2-one
- 5
- 2-(tert-butyl-dimethyl-silanyloxy)-5H-dibenzo[b,f]azepine-5-carboxylic acid 2,4-dimethoxy-benzylamide
- 6
- 2-hydroxycarbamazepine
- 7-EFC
- 7-ethoxy-4-trifluorocoumarin
- Received April 29, 2002.
- Accepted July 21, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|